On the 7th and 8th of April 2025, the European Society of Clinical Pharmacy (ESCP) will host its Spring Workshop in Egmond aan Zee, the Netherlands, focusing on a highly topic for the further development of clinical pharmacy: the prescribing pharmacist. As healthcare systems face increasing pressures from aging populations, rising comorbidities, and resource constraints in both primary and secondary care, the need for innovative and sustainable approaches to patient care is more urgent than ever. Redistributing tasks and responsibilities among healthcare professionals could help maintain the quality and accessibility of patient care [
1]. In this context, several countries (e.g., UK, Brazil and New Zealand) have granted (in)dependent prescribing authority to pharmacists, which has shown to be both safe and effective [
2]. Independent pharmacist prescribing refers to the legal authority granted to pharmacists to prescribe medications without the need for direct supervision by a physician or other healthcare professional. In this capacity, pharmacists can assess, make clinical decisions, and prescribe autonomously, e.g. the current prescribing model in the UK [
3]. Dependent prescribing models involve prescribing in the context of protocols, agreements or collaboration with physicians, e.g. the current prescribing in New Zealand [
3]. However, pharmacist prescribing rights can be different in different provinces/states within one country, e.g. USA and Canada [
4,
5]. …
